Wedbush analyst Liana Moussatos views the selloff yesterday in shares of Aimmune Therapeutics as overdone. The Institute for Clinical and Economic Review on Wednesday released a final report on emerging desensitization treatments for peanut allergy and compared the clinical effectiveness and value of Aimmune's AR101, DBV Technologies' (DBVT) Viaskin and non-commercialized oral immunotherapy for treatment of peanut allergy, Moussatos tells investors in a research note. However, the ICER report excluded long-term desensitization and patient quality-of-life results for AR101 and hence failed to recognize the full value of AR101 immunotherapy for peanut allergy, says the analyst. She sees an "excellent entry point" into Aimmune shares following yesterday's selloff and reiterates an Outperform rating on the name wih a $79 price target.